Results 71 to 80 of about 28,540 (254)

Factors Influencing the Binding of HIV‐1 Protease Inhibitors: Insights from Machine Learning Models

ChemMedChem, EarlyView.
Machine learning unlocks the secrets of HIV‐1 protease inhibition, paving the way for data‐driven antiviral drug design. This study analyzes crystallographic data from hundreds of protein–ligand complexes, predicting ligand binding affinity with over 85% accuracy.
Yaffa Shalit, Inbal Tuvi‐Arad
wiley   +1 more source

Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2

Viruses
Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase.
Irene Wanjiru Kiarie, Gyula Hoffka, Manon Laporte, Pieter Leyssen, Johan Neyts, József Tőzsér, Mohamed Mahdi   +6 more
doaj   +1 more source

Dynein Regulators Are Important for Ecotropic Murine Leukemia Virus Infection [PDF]

, 2016
Indexación: Web of Science.During the early steps of infection, retroviruses must direct the movement of the viral genome into the nucleus to complete their replication cycle.
Arriagada, Gloria, Cancino, Jorge, Goff, Stephen P., Opazo, Tatiana, Valle-Tenney, Roger   +4 more
core   +1 more source

Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long‐Acting Intramuscular Injections

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Long‐acting cabotegravir is approved for HIV treatment and prevention. To guide management of dosing deviations and interruptions, concentration‐time profiles for monthly and every 2 months regimens were simulated using a population pharmacokinetic (PPK) model.
Kelong Han, Ronald D. D'Amico, William R. Spreen, Susan L. Ford   +3 more
wiley   +1 more source

Acidic Nanoparticles Prevent HIV Pre‐Exposure Prophylaxis (PrEP)‐Induced Oligodendrocyte Impairments by Restoring Lysosomal pH in Adolescent Models

Glia, EarlyView.
Pre‐exposure prophylaxis (PrEP) inhibits oligodendrocyte differentiation. PrEP inhibits oligodendrocyte differentiation through lysosome deacidification. Acidic nanoparticles prevent PrEP‐induced inhibition of oligodendrocyte differentiation. ABSTRACT A disproportionate percentage of adolescents are diagnosed with human immunodeficiency virus (HIV) in ...
Caela C. Long, Lindsay K. Festa, Melanie Cruz‐Berrios, Teshawn D. Johnson, Claire H. Mitchell, Kelly L. Jordan‐Sciutto, Judith B. Grinspan   +6 more
wiley   +1 more source

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening

Molecules, 2019
Currently, an increasing number of drugs are becoming available to clinics for the treatment of HIV infection. Even if this targeted therapy is highly effective at suppressing viral replication, caregivers are facing growing therapeutic failures in ...
Cindy Aknin, Elena A. Smith, Christophe Marchand, Marie-Line Andreola, Yves Pommier, Mathieu Metifiot   +5 more
doaj   +1 more source

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana

Viruses, 2021
There are limited real-world mutational and virological outcomes data of treatment-experienced persons diagnosed with HIV-1 subtype C (HIV-1 C) who are failing Integrase Strand Transfer Inhibitor-based regimens. Requisition forms sent for HIV-1 genotypic
Kaelo K. Seatla, Dorcas Maruapula, Wonderful T. Choga, Tshenolo Ntsipe, Nametso Mathiba, Mompati Mogwele, Max Kapanda, Bornapate Nkomo, Dinah Ramaabya, Joseph Makhema, Mompati Mmalane, Madisa Mine, Ishmael Kasvosve, Shahin Lockman, Sikhulile Moyo, Simani Gaseitsiwe   +15 more
doaj   +1 more source

Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa [PDF]

, 2018
HIV-Integrase (IN) has proven to be a viable target for highly specific HIV-1 therapy. We aimed to characterize the HIV-1 IN gene in a South African context and identify resistance-associated mutations (RAMs) against available first and second ...
A Hombrouck, A Häggblom, A Stamatakis, A Trickey, AC Pineda-Peña, C Garrido, CB Passaes, D Struck, DJ Hazuda, DO Passos, E Heger, E Ndashimye, F Danion, F Raffi, GB Jacobs, GB Jacobs, H Taha, I Malet, JA Grobler, K Anstett, K Anstett, K Shimura, K Singh, K Steegen, KV Laethem, LF Johnson, M Casadellà, M Kobayashi, M Tsiang, MF Oliveira, NI Paton, O Goethals, P Cahn, P Swanson, PK Quashie, PO Bessong, R Kantor, RK Gupta, S Fourati, S-Y Rhee, S-Y Rhee, SL Walmsley, T Doyle, T Yoshinaga, W Huang, Z Temesgen   +45 more
core   +3 more sources

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

The Journal of Clinical Pharmacology, EarlyView.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora, Hui Liu, John Ling, Jason T. Hindman, Dhananjay D. Marathe   +4 more
wiley   +1 more source

From ligand to complexes: inhibition of HIV-1 Integrase by beta-diketo acid metal complexes [PDF]

, 2006
Recently, a class of compounds bearing a β-diketo acid moiety have emerged as the most promising lead in anti-HIV-1 IN drug discovery. It is believed that the β-diketo acid pharmacophoric motif could be involved in a functional sequestration of one or ...
Al-Mawsawi, Laith Q., Bacchi, Alessia, Carcelli, Mauro, Derudas, Marco, Fisicaro, Emilia, Gates, Paul, Neamati, Nouri, Rogolino, Dominga, Sechi, Mario   +8 more
core